This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page
CommitmentHeritageInitiativesInnovationPortfolio

Menu

Close

Information on how to access prescribing information and adverse event reporting can be found at the bottom of this page.

Focus on Innovation

One in two people will develop some form of cancer within their lifetime.1 That’s why nothing is more personal, or more urgent, than our goal to develop a new generation of potential therapies which could improve millions of lives.2

 

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer.

 

Over the past decade, we’ve taken new approaches to translate scientific research into effective medicines for cancer patients. Now, our scientists are working tirelessly to develop a new generation of potential treatments across multiple cancers and tumour types.

Focus on Innovation

We are focused on the development of biologics, small molecules, immunotherapies and biosimilars for a range of tumour types: 

Example

We're also exploring genetic, phenotypic and functional biomarkers to help guide clinical research strategies and ensure the right patients are treated with the right medicines. Our goal is to develop therapies with potentially transformational outcomes.

Specific areas of interest include:

  • new chemical entities (NCEs)
  • antibody-drug conjugates (ADCs)
  • oncogenic drivers / cell signalling
  • anti-angiogenics
  • cancer stem cells, metabolism and epigenetics
  • bi-specifics
  • vaccines
Related Content
Our Oncology Portfolio

Our portfolio of treatments stretches across multiple indications, including breast, genitourinary, blood and lung cancers.

Find out moreLoading
Commitment to Oncology

We're proud to partner with organisations that share our purpose to deliver the right treatment for each patient, at the right time.

Find out moreLoading
Our Oncology Heritage

For over two decades, we have worked tirelessly in our pursuit to develop innovative and accessible treatments for those living with cancer. 

Find out moreLoading
Initiatives in Oncology

In addition to manufacturing medicines, we're engaged in a number of initiatives that we hope will improve the lives of those impacted by cancer.

Find out moreLoading
Prescribing Information for Great Britain and Northern Ireland:

​​​​​​
Besponsa®▼ (inotuzumab ozogamicin) Ibrance® (palbociclib)
Lorviqua®▼ (lorlatinib) Mylotarg®▼ (gemtuzumab ozogamicin)
Ruxience®▼ (rituximab) Trazimera® (trastuzumab)
Xalkori® (crizotinib) Zirabev®▼ (bevacizumab)


References:

1. NHS UK. Cancer: Overview. Available at: https://www.nhs.uk/conditions/cancer/. Last accessed September 2023. 
2. Pfizer data on file. 

PP-UNP-GBR-7080. October 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284. November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​